News
Hims & Hers Jumps 18.2% on Incredible 111% Revenue Growth
Hims & Hers (NYSE: HIMS) stock soared 18.2% in trading on Tuesday after the company reported first-quarter revenue growth of 111% and an increase in 2025 guidance. The results were phenomenal and a short squeeze likely helped, which Travis Hoium discusses in this video.
We recently published a list of Here’s What Fueled These 10 Firms’ Surge. In this article, we are going to take a look at ...
Hims & Hers reports 111% YoY sales growth & 70%+ gross margin. Discover their growth potential, risks, & why it's a Buy ...
24/7 Wall St. on MSN1d
Hims & Hers (HIMS) Blows Out Earnings ExpectationsHims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...
Hims & Hers Health partners with Novo Nordisk (NVO) to offer Wegovy, boosting weight-loss solutions. See why I remain ...
Hers is a telehealth company that offers products for hair loss, skin care, sexual health, and mental health. Hers offers both prescription and nonprescription products. A person wishing to ...
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity. In a joint venture with Novo Nordisk ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback